Omeros Logo     Print Page  |  Close Window

Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$19.56
Change (%) Stock is Up 0.55 (2.89%)
Volume825,931
Data as of 12/15/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
12/12/17Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients
-- FDA Also Grants Additional Market Exclusivity -- SEATTLE--(BUSINESS WIRE)--Dec. 12, 2017-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that the U.S. F... 
 Printer Friendly Version
11/09/17Omeros Corporation Reports Third Quarter 2017 Financial Results
Conference Call Today at 4:30 p.m. ET SEATTLE--(BUSINESS WIRE)--Nov. 9, 2017-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced recent highlights and developm... 
 Printer Friendly Version
11/06/17Extended Improvement in OMS721-Treated Patients with IgA Nephropathy Presented at American Society of Nephrology Annual Meeting
SEATTLE--(BUSINESS WIRE)--Nov. 6, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting in New Orleans. These data describe up to one-year follow-up of patients treated with OMS721 in the glomerulonephropathy Phase 2 clinical trial. OMS721 is Omeros’ lead hu... 
 Printer Friendly Version
11/06/17Omeros Corporation to Announce Third Quarter 2017 Financial Results on November 9, 2017
SEATTLE--(BUSINESS WIRE)--Nov. 6, 2017-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2017 financial results for the period ended September 30, 2017, on Thursday, November 9, 2017, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. Conference Call Details To acces... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2016 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.